2018 Executive Sponsors
2018 Associate Sponsors
2018 Supporting Partners
2018 Educational Partners
2018 Media Partners
2018 Executive Sponsors
Adaptive Biotechnologies is the pioneer and leader in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. Adaptive is bringing the accuracy and sensitivity of its immunosequencing platform into laboratories around the world to drive groundbreaking research in cancer and other immune-mediated diseases. Adaptive also translates immunosequencing discoveries into clinical diagnostics and therapeutic development to improve patient care. Learn more at www.adaptivebiotech.com
Imaging Endpoints (IE) is a mission driven research and imaging CRO with offices in Scottsdale, Arizona and Waltham, Massachusetts. We specialize in providing the industry’s leading imaging expertise and most advanced technologies coupled with exquisite services. Our experience extends from translational to phase 3 trials and every step in-between. Our organization is unique in that it is owned by a team of over 40 in-house radiologists and nuclear medicine physicians that specialize in advanced imaging technologies. Our comprehensive services span all aspects of trial planning and conduct, including protocol development, site qualification and standardization, real-time image receipt/QC and reads, data management, regulatory compliance and preparation for meetings/submissions to regulatory authorities. Our Rapid Detection and Assessment of Response program (RaDAR) is designed to accelerate product development by integrating the most advanced imaging technologies into clinical trials. At Imaging Endpoints, our capabilities go above and beyond the typical imaging core lab offering. Learn more at www.imagingendpoints.com
Mitra Biotech is a global leader in advancing personalized cancer treatment and empowering drug development & discovery. Our phenotypic CANscript platform delivers powerful insight for our biopharma partners. Because CANscript conserves the native tumor microenvironment and delivers 1:1 clinical correlation, it can be used to predict response of an indication to a specific drug (or drug combination), or to better understand MOA of a given compound. Founded in 2010, Mitra is headquartered in Boston and maintains a significant research and laboratory presence in Bangalore, India. Visit us at www.mitrabiotech.com
NanoString Technologies provides life science tools for translational research and molecular diagnostics. nCounter® digital molecular barcoding enables simultaneous measurement of hundreds of genes, miRNAs, proteins, or copy number variations. Precise and highly sensitive, this technology facilitates numerous applications including NanoString’s first diagnostic product, the Prosigna® Prognostic Breast Cancer Gene Signature Assay. Learn more at www.nanostring.com.
NeoGenomics is a premier cancer diagnostics and pharma services company. We serve the needs of oncologists, pathologists, pharmaceutical companies, academic centers, and other healthcare professionals with innovative diagnostic, prognostic and predictive testing. We provide anatomic pathology, flow cytometry, FISH, cytogenetics, molecular, and genomic technologies. Our experience with companion and complementary diagnostics is unparalleled and we are the lab of choice for the pharma industry for clinical trial lab services. Visit www.neogenomics.com.
2018 Associate Sponsors
Learn more about us at http://apogenix.com/en.
BeiGene is a global biotechnology company focused on the discovery and development of innovative drugs to treat cancer. Our drug discovery engine has generated four assets entering late-stage clinical development, as well as several drugs in preclinical development. Each program has potential meaningful differentiation, and our broad portfolio offers opportunities for combinations. BeiGene has access to huge numbers of patients in China that enable us to better identify therapies with the potential to be best-in-class treatments. Learn more at www.beigene.com.
Learn more about us at www.bostonimmunetech.com.
Cancer Genetics, Inc. is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India, Australia and China. The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Learn more about us at www.cgix.com.
Cytel is shaping the future of drug development. As the world’s largest Biometrics CRO, we improve our customers’ chances of success through expert trial design, efficient operational implementation and reliable clinical data management. Learn about our clinical research services capabilities, in addition to the Cytel line of statistical and operations-support software at www.cytel.com.
Defined Health is a leading biopharmaceutical asset development strategy consultancy with 25+ years of experience. Our consultants hold advanced degrees in science, medicine and business, and have industry experience in business development, commercial evaluation, finance, licensing, drug discovery and R&D. Our clients include top global pharma, large cap biotech, specialty pharma and hundreds of pre-commercial biotech and platform technology companies. Our work encompasses asset evaluation, early commercial strategy, indication prioritization and sequencing, life-cycle management and search and evaluation. Learn more at www.definedhealth.com.
Exicure is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure’s proprietary 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure’s lead programs address inflammatory diseases, genetic disorders and oncology. Exicure is based outside of Chicago, Ill. Learn more about us at www.exicuretx.com.
ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development – from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 84 locations in 38 countries and has approximately 12,300 employees. Further information is available at www.iconplc.com.
KIYATEC prioritizes accurate ex vivo prediction of patients’ drug response, focused primarily on data correlation to human clinical outcomes. Our drug response profiling services utilize phenotypic 3D cell-based models for predicting patient response. KIYATEC’s 3D perfusion tissue microenvironments are particularly useful for investigating the efficacy of both immuno-oncology therapies and chemotherapeutics. For more information, please visit us at www.kiyatec.com
Learn more about us at http://oncorus.com.
As a leading central review core lab for clinical trials, PAREXEL offers multiple solutions to standardize central oncology endpoint assessments. With PAREXEL you are supported by our in-house medical scientific and medical writing expertise, complemented by specialized key opinion leaders and scientific advisors in oncology. For more information, visit www.PAREXEL.com.
Personalis, Inc is a leading precision medicine company focused on advanced NGS-based clinical diagnostic, clinical trial and research services for cancer and inherited genetic disease. Personalis also provides DNA sequencing and data analysis of human genomes. Our ACE Exome and Transcriptome technology is designed to obtain the most comprehensive and accurate tumor molecular profile for immuno-oncology applications. The company’s clinical laboratory is GCP compliant, CLIA licensed and CAP accredited. Visit www.personalis.com.
Axio Research offers a comprehensive range of statistical genetics and genomics services to clients undertaking drug discovery and companion diagnostics development. Merging deep experience in statistical genetics, bioinformatics, and biostatistics with clinical understanding, Axio applies leading-edge statistical and computational methods to support and expedite genomic discovery. Reach us at: info@AxioResearch.com. Learn more about us at www.axioresearch.com.
Caprion is a specialty CRO providing laboratory services to pharmaceutical/biotechnology companies with GCP/GLP/GCLP capabilities. Caprion’s ImmuneCarta® Division, offers multi-parametric flow cytometry, cytokine testing, and ELISpot for analyses of innate and adaptive immune responses. Caprion’s ProteoCarta™ Division leverages its expertise in mass spectrometry for protein analysis in support of biomarkers development. Learn more about us at www.caprion.com
Intrinsic Imaging is an FDA audited, ISO 9001, ISO 13485 and ISO 22301 certified and GAMP® 5 compliant medical imaging core lab. At Intrinsic, we have the team, the technology and the therapeutic expertise to manage your entire medical imaging trial providing comprehensive services in support of Phase I-IV Clinical Trials. For more information, please visit www.intrinsicimaging.com